Amylyx Pharmaceuticals (AMLX) Profit After Tax (2021 - 2026)
Amylyx Pharmaceuticals (AMLX) posted quarterly Profit After Tax of -$41.3 million for Q1 2026, down 14.97% year-over-year from -$48.6 million in Q1 2025, and down 25.11% quarter-over-quarter from -$33.0 million in Q4 2025.
Amylyx Pharmaceuticals (AMLX) Profit After Tax (2021 - 2026) Analysis & Trends
Amylyx Pharmaceuticals' Profit After Tax history runs 6 years deep, the most recent figure standing at -$41.3 million for Q1 2026.
- In Q1 2026, Profit After Tax fell 14.97% year-over-year to -$41.3 million; the TTM figure through Mar 2026 stood at -$150.1 million (up 31.41% YoY), while the FY2025 annual figure was -$144.7 million, up 52.03% from the prior year.
- Profit After Tax for Q1 2026 stood at -$41.3 million, down from -$33.0 million in the prior quarter.
- The five-year high for Profit After Tax was $22.1 million in Q2 2023, with the low at -$118.8 million in Q1 2024.
- The 5-year median for Profit After Tax is -$41.3 million (2026), against an average of -$37.5 million.
- The sharpest annual moves came in 2023 and 2024: Profit After Tax jumped 140.83% in 2023, then tumbled 7652.0% in 2024.
- Amylyx Pharmaceuticals' Profit After Tax stood at -$42.7 million in 2022, then soared by 111.08% to $4.7 million in 2023, then tumbled by 893.62% to -$37.5 million in 2024, then increased by 12.11% to -$33.0 million in 2025, then fell by 25.11% to -$41.3 million in 2026.
- Business Quant data shows AMLX's Profit After Tax at -$41.3 million in Q1 2026, -$33.0 million in Q4 2025, and -$34.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 86.50 Bn | 85.53 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.71 Bn | 39.05 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 30.86 Bn | 29.18 Bn | 1.80 Bn | 691.00 Mn |
| 4 | Takeda Pharmaceutical | 28.50 Bn | 22.70 Bn | 5.10 Bn | 710.56 Mn |
| 5 | United Therapeutics | 22.06 Bn | 19.40 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.84 Bn | 17.95 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.55 Bn | 15.16 Bn | 935.80 Mn | 149.10 Mn |
| 8 | Vireo Growth | 11.86 Bn | 11.71 Bn | 59.30 Mn | -20.30 Mn |
| 9 | Elanco Animal Health | 11.77 Bn | 11.24 Bn | 798.00 Mn | 54.00 Mn |
| 10 | Amylyx Pharmaceuticals | 3.91 Bn | 3.91 Bn | - | -43.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -43.64 Mn |
| Mar 31, 2026 | -41.28 Mn |
| Dec 31, 2025 | -33.00 Mn |
| Sep 30, 2025 | -34.39 Mn |
| Jun 30, 2025 | -41.44 Mn |
| Mar 31, 2025 | -35.91 Mn |
| Dec 31, 2024 | -37.55 Mn |
| Sep 30, 2024 | -72.70 Mn |
| Jun 30, 2024 | -72.70 Mn |
| Mar 31, 2024 | -118.79 Mn |
| Dec 31, 2023 | 4.73 Mn |
| Sep 30, 2023 | 20.89 Mn |
| Jun 30, 2023 | 22.07 Mn |
| Mar 31, 2023 | 1.57 Mn |
| Dec 31, 2022 | -42.70 Mn |
| Sep 30, 2022 | -53.76 Mn |
| Jun 30, 2022 | -54.07 Mn |
| Mar 31, 2022 | -47.85 Mn |
| Dec 31, 2021 | -28.34 Mn |
| Sep 30, 2021 | -23.14 Mn |